Evidence map›Paper›PMID 38709106›Full record

ArticleJournal of virology2024

Human coronavirus OC43 nanobody neutralizes virus and protects mice from infection.

Amy Adair, Li Lynn Tan, Jackson Feng, Jason Girkin, Nathan Bryant, Mingyang Wang, Francesca Mordant, Li-Jin Chan, Nathan W Bartlett, Kanta Subbarao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Amy Adair *The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Li Lynn Tan *The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Jackson FengThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Jason Girkin3College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia.
Nathan Bryant3College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia.
Mingyang WangDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia.
Francesca MordantDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia.
Li-Jin ChanThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Nathan W Bartlett3College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia.
Kanta SubbaraoDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia.
Phillip PymmThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Wai-Hong ThamThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.ORCID 0000-0001-7950-8699

Funding

DHAC | National Health and Medical Research Council (NHMRC) GNT2016908DHAC | National Health and Medical Research Council (NHMRC) GNT2021267
6 · The paper itself

Abstract

Human coronavirus (hCoV) OC43 is endemic to global populations and usually causes asymptomatic or mild upper respiratory tract illness. Here, we demonstrate the neutralization efficacy of isolated nanobodies from alpacas immunized with the S1 IMPORTANCE: The pandemic potential presented by coronaviruses has been demonstrated by the ongoing COVID-19 pandemic and previous epidemics caused by severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus. Outside of these major pathogenic coronaviruses, there are four endemic coronaviruses that infect humans: hCoV-OC43, hCoV-229E, hCoV-HKU1, and hCoV-NL63. We identified a collection of nanobodies against human coronavirus OC43 (hCoV-OC43) and found that two high-affinity nanobodies potently neutralized hCoV-OC43 at low nanomolar concentrations. Prophylactic administration of one neutralizing nanobody reduced viral loads in mice infected with hCoV-OC43, showing the potential for nanobody-based therapies for hCoV-OC43 infections.

Indexed as

Antibodies, NeutralizingAntibodies, ViralCamelids, New WorldCoronavirus InfectionsCoronavirus OC43, HumanSingle-Domain AntibodiesSpike Glycoprotein, CoronavirusViral LoadAnimalsCrystallography, X-RayDisease Models, AnimalEpitopesFemaleHumansMiceMice, Inbred BALB CAntibodies, NeutralizingAntibodies, ViralEpitopesSingle-Domain AntibodiesSpike Glycoprotein, Coronavirusanti-viral therapeuticscoronavirusnanobodiesX-ray crystallography

Identifiers

PMID38709106
PMCPMC11237593

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.